Ed Schuuring | head lab of Molecular Pathology
University of Groningen

Ed Schuuring, head lab of Molecular Pathology, University of Groningen

Three decades his research focuses on the identification of prognostic/predictive epigenetic and molecular markers for clinical outcome, response to chemo-radiotherapy, gene-targeted therapy and treatment-resistance in lung, GIST, head&neck cancer, as well as the early detection of cervical cancer in scrapings. More recently his interest expanded to monitoring plasma ctDNA as a bloodborne-based molecular tool to predict MRD, high risk to develop metastasis and response to targeted and immuno-therapy. He is heading the laboratory of Molecular Pathology offering the latest innovative methods for treatment-decision-making in the region North-Netherlands. Since 1997 he is active in (inter)national committees and advisory boards on implementing Molecular Pathology, the organisation of international proficiency mutation testing in lung tissue biopsies and plasma ctDNA, and co-authored various international guidelines on Molecular Pathology. He graduated in Medical Biology in 1985 and PhD in 1993 in Molecular Biology (University of Amsterdam). He worked as a staff clinical scientist in Molecular Pathology at LUMC (1991-2000) and UMCG (2001-now).


Festival of Biologics Day 3 @ 12:10

Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors

  • Circulating tumor DNA (ctDNA) is shed into the bloodstream and serves as potential predictive or prognostic biomarker
  • Changes in mutantctDNAlevels in plasmacfDNAdetected withddPCRorctNGSare associated with overall survival in NSCLC patients treated with immune checkpoint inhibitors
  • Interpretation ofctDNANGS results needs to account for clonal hematopoiesis of indeterminate potential (CHIP) representing variants incfDNAunrelated to the lung cancer
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers